XOMA Corporation (XOMA): Rasio kapitalisasi pasar marang pendapatan

XOMA Royalty (XOMA) stock dynamics depend on the outcome of partners' clinical trials, which creates a risk of asset impairment. The revenue multiple on the GURU.Markets daily price chart reflects these fluctuations, where the indicator value reaches 14.60. XOMA Royalty (XOMA) acts as a financial catalyst for the biotech sector by acquiring rights to future payments and maintains its status as a trusted partner with a diversified license portfolio.

XOMA XOMA Royalty: Multiplikator P/S ing interval 04.07.2022 - 25.07.2026

Rincian metrik lan analitis perusahaan XOMA Royalty (XOMA)

- nilai saham lan prakiraan konsensus rega:

Rega saham XOMA Corporation|XOMA - Bagan rega target

- data kapitalisasi bursa:

Nilai pasar XOMA|XOMA - Nilai Perusahaan

- indikator kapitalisasi buku:

Nilai Akuntansi saben Saham XOMA Royalty|XOMA - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku xoma.com|XOMA - Gunggung Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

- data bathi bisnis lan rasio investasi:

XOMA - Bathi resik perusahaan|Penghasilan resik sing dikarepake XOMA Royalty|XOMA - Rasio rega marang bathi|Rasio prakiraan rega marang bathi XOMA Corp|XOMA - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan XOMA|XOMA - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) XOMA Royalty|XOMA - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan xoma.com|XOMA - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep XOMA Royalty

- rincian pendapatan lan dodolan emiten:

XOMA - Dodolan perusahaan|Volume dodolan sing dikarepake perusahaan XOMA Corp|XOMA - Kapitalisasi marang pendapatan|Kapitalisasi marang prakiraan pendapatan XOMA Royalty|XOMA - Wutah dodolan YoY sajrone rolas wulan kepungkur

Analisis fundamental perusahaan:XOMA (XOMA Corp)

XOMA Royalty operates under a debt-free model where revenues depend on external regulatory approvals of partners' drugs. This metric, calculated as the ratio of market capitalization to annual revenue, measures the cost of one dollar of sales, allowing investors to determine the degree of overpayment relative to the issuer's actual cash flows through the company's revenue valuation on GURU.Markets.

Perusahaan pesaing

TPL (Texas Pacific Land Corporation) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Royalty Pharma Corp RPRX|Rasio kapitalisasi pasar marang pendapatan VNOM|Black Stone Minerals LP - Multiplikator P/S|Rega marang dodolan Northern Oil and Gas, Inc.|DMLP: Multiplikator P/S|SBR - Koefisien rega marang pendapatan|VTS (Vitesse Oil) - Multiplikator P/S|Rega marang dodolan Permian Basin Royalty PBT|Rasio rega marang pendapatan TXO Partners LP (TXO)|GRNT (Granite Ridge Resources) - Rasio kapitalisasi pasar marang pendapatan|San Juan Basin Royalty Trust - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan STEX|SRL - Rasio rega marang pendapatan|Koefisien rega marang pendapatan MV Oil Trust, Inc. MVO|PVL: Multiplikator P/S|Rasio kapitalisasi marang pendapatan VOC|Kapitalisasi marang pendapatan CRT|Kapitalisasi marang pendapatan PermRock Royalty Trust Inc (PRT)|Kapitalisasi marang pendapatan RMCO (royaltymgmtcorp.com)|CKX Lands Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S MTR (Mesa Royalty Trust, Inc.)|BP Prudhoe Bay Royalty Trust Inc (BPT) - Rega marang dodolan|phxmin.com - Multiplikator P/S|STR - Multiplikator P/S